The Inhibitory Properties of a Novel, Selective LMTK3 Kinase Inhibitor
- Int J Mol Sci. 2023 Jan 3;24(1):865. doi: 10.3390/ijms24010865.
- 1. Department of Biochemistry and Biomedicine, School of Life Sciences, University of Sussex, Brighton BN1 9QG, UK.
- 2. Institute of Biosciences and Applications, National Centre for Scientific Research "Demokritos", 15341 Athens, Greece.
- 3. Department of Surgery and Cancer, Imperial College, London SW7 2BX, UK.
- 4. Sussex Drug Discovery Centre, School of Life Sciences, University of Sussex, Brighton BN1 9QG, UK.
Recently, the oncogenic role of lemur tyrosine kinase 3 (LMTK3) has been well established in different tumor types, highlighting it as a viable therapeutic target. In the present study, using in vitro and cell-based assays coupled with biophysical analyses, we identify a highly selective small molecule LMTK3 inhibitor, namely C36. Biochemical/biophysical and cellular studies revealed that C36 displays a high in vitro selectivity profile and provides notable therapeutic effect when tested in the National Cancer Institute (NCI)-60 Cancer cell line panel. We also report the binding affinity between LMTK3 and C36 as demonstrated via microscale thermophoresis (MST). In addition, C36 exhibits a mixed-type inhibition against LMTK3, consistent with the inhibitor overlapping with both the adenosine 5'-triphosphate (ATP)- and substrate-binding sites. Treatment of different breast Cancer cell lines with C36 led to decreased proliferation and increased Apoptosis, further reinforcing the prospective value of LMTK3 inhibitors for Cancer therapy.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: c-Met/HGFRResearch Areas: Cancer